Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Caio M. Rocha LimaDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,Correspondence[email protected]

Soley BayraktarDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,

Aurea M. FloresDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,

Jessica MacIntyreDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,

Alberto MonteroDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,

Joaquina C. BarandaDepartment of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA,

John WallmarkAssociates in Oncology/Hematology, PC, Rockville, Maryland, USA,

Chia PorteraGenentech, Inc., South San Francisco, California, USA

Rajiv RajaGenentech, Inc., South San Francisco, California, USA

Howard SternGenentech, Inc., South San Francisco, California, USA

Stephanie Royer-JooGenentech, Inc., South San Francisco, California, USA

Lukas C. AmlerGenentech, Inc., South San Francisco, California, USA

show all

Abstract

In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Information for

Open access

Opportunities

Help and information

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature